Rheumnow Podcast

Dr. Jack Cush reviews the news and journal reports from RheumNow.com Top 5 reasons to attend RheumNow Live 2026 1. Its cold and far, but you can be there virtually, online 2. Ffull access to handouts, slides & downloads 3. Saturday concert with Colin Boyd 4. Rohit Agarwal does TWO STEP talks! 5. Download 400+ rheumatology review Questions REGISTER at - RheumNow.live

Join us for our next webinar: Focus on Guidelines. Panelists will discuss their approaches to a range of difficult cases in multiple areas, including rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis and vasculitis, and discuss how they apply the guidelines in everyday practice. You’ll hear different perspectives and practical tips you can use in clinic. Panelists: Audrey Gibson, PA-C Benjamin A. Smith, PA-C Jack Cush, MD Following the discussion, join a live Q & A with the panelists. Register now to reserve your spot! This is our second Tuesday Night Rheumatology this month as part of our Mission: APP Partners in Care campaign

Dr. Jack Cush reviews the news and reports from the past two weeks on RheumNow.Com

Dr. Jack Cush reviews rheumatology's highlights, advances and noteworthy trends from the past year - 2025!

1- Sex & the Rheum Patient (12:17) 2- Pain Management (17.58) 3- Lifestyle (15.38)

This podcast is part one of the Mission: APP Partners in Care Therapeutic Update Series called Underserved and under-treated. This podcast includes videos from: Daric Mueller, PA-C, Rachel Busch-Feuer, DNP, Betsy Kirchner, DNP, Lindsay Tom, PA-C and Vanessa Hill, NP-C

Dr. Jack Cush reviews the news, announcements and journal articles from this past week on RheumNow.com. More on Variable bendability, a better way to treat RA, and a novel advance for GLP1a in PsA; and 2026 Resolutions!

Features Dr. Jack Cush

Panelists: Vanessa Hill, NP-C Lindsay Tom, PA-C Barb Slusher Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. Who would've thunk - a PsA FMF connection? Labs to diagnose SSc-ILD? IgA-RF may be important or RZV may not work in JAK inhibitor treated patients?

Join us for our third webinar this month, discussing APP Controversies and Misconceptions. Panelists will cover a range of topics, including APP roles impact; models of care; independence; seeing new patients and complex cases; and more. Panelists: Daric A. Mueller, PA-C Lisa Carnago, MSN, FNP-C, RN Jack Cush, MD

Dr. Jack Cush reviews the news, journal and regulatory reports from this past week on RheumNow.com. B cell drugs in SLE and ITP, biomarkers in GCA & PSS and great videos by APPs.

Join us for our next webinar: Focus on Guidelines. Panelists will discuss their approaches to a range of difficult cases in multiple areas, including rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis and vasculitis, and discuss how they apply the guidelines in everyday practice. You’ll hear different perspectives and practical tips you can use in clinic. Panelists: Audrey Gibson, PA-C Benjamin A. Smith, PA-C Jack Cush, MD Following the discussion, join a live Q & A with the panelists. Register now to reserve your spot! This is our second Tuesday Night Rheumatology this month as part of our Mission: APP Partners in Care campaign

Drs. Jack Cush and Artie Kavanaugh preview the upcoming RNL 2026 meeting in Dallas, TX on February 7 & 8, 2026. Register at RheumNow.Live Below is the program: Saturday, February 7, 2026, 7:50 - 8:00 am Welcome & Introductions Drs. Cush and Kavanaugh 8:00 - 10:00 am POD I - Rheumatoid Arthritis: Achieving Better Outcomes 8:00 – 8:30 am Mortality in RA: A Story of Decline, Delay, or Plateau? Elena Myasoedova, MD 8:30 – 9:00 am The Mucosal Hypothesis of Rheumatoid Arthritis Kristen Demoruelle, MD 9:00 – 9:30 am ILD in RA – Recent Advances Jeffrey Sparks, MD 9:30 – 10:00 am Rheumatoid arthritis Faculty Q&A 10:00 - 10:15 am STEP 1: Placebos in Rheumatology Andreas Kerschbaumer, MD 10:15 -10:30 am STEP 2: Disease Modification in Osteoarthritis Tuhina Neogi, MD PhD 10:30 – 11:05 Break 11:05 - 12:10 pm POD II – Advancing Practice 11:05 – 11:30 am Obesity & Inflammation: Weight Management in Rheumatology Uzma Haque, MD 11:30 - 11:55 am Mitigating risk in Rheum Pts undergoing surgery Susan Goodman, MD 11:55 -12:10 pm Practice Panel Faculty Q&A 12:10 – 1:00pm Lunch 1:00 – 3:00 pm POD III – Decisions in Psoriatic Arthritis 1:00 - 1:30 pm Paradoxical Psoriasis and Strange Reactions Joseph Merola, MD 1:30 - 2:00 pm Why Do Plain X rays in Psoriatic Arthritis Arthur Kavanaugh, MD 2:00 - 2:30 pm IL-23 vs IL-17 inhibitors in PsA Andre Ribero, MD 2:30 - 3:00 pm Past, Present & Future of Gout Robert Terkeltaub, MD 3:00 - 3:30 pm Psoriatic Faculty Q&A 3:30 - 4:05 pm Break 4:05 - 4:20 pm STEP 3: Helicobacter Pylori update Byron Cryer, MD 4:20 - 4:35 pm STEP 4: History of Gout Robert Terkeltaub, MD 4:35 – 5:15 pm Keynote Address: 50 Years of Osteoporosis Michael McClung, MD 5:30 – 7:00 pm Reception Sunday, February 8, 2026 Day TOPIC Speaker 7:50-8:00 am Welcome & Introductions Drs. Cush and Kavanaugh 8:00 - 10:00 am POD IV – Staying Ahead of Spondyloarthritis 8:00 – 8:30 am Diagnosing Axial Spondyloarthritis in 2026 Denis Poddubnyy, MD 8:30 – 9:00 am Spondyloarthritis Complications Jessica Walsh, MD 9:00 – 9:30 am 2026 Advances in Spondyloarthritis Catherine Bakewell, MD 9:30 – 10:00 am Spondyloarthritis Faculty Q&A 10:00 – 10:15 am STEP 5: Asymptomatic Elevation of CK Rojit Agarwal, MD MS 10:15 – 10:30 am STEP 6: Update on Myositis Antibodies Rojit Agarwal, MD MS 10:30 – 11:05 am Break 11:05 – 12:10 am POD V – Highlights in Autoimmune Disease 11:05 - 11:35 am SMILE Study – Hydroxychloroquine in ANA+ Arthralgia Nancy Olsen, MD 11:35 – 12:05 am Sjogren's Treatment Landscape in 2026 Matthew Baker, MD 12:05 - 12:20 pm Autoimmune Faculty Q&A 12:20 – 1:25 pm POD VI - Large & Small Vessel Vasculitis 12:20 – 12:45 pm Embracing Relapses in PMR and GCA Michael Putman, MD 12:45 - 1:10 pm Small vessel vasculitis Clay Cockerell, MD 1:10 - 1:25 pm Vasculitis Faculty Q&A 1:30 pm Adjourn

QD300: Flare or Beware (featuring Lindsay Tom, PA-C and Phong Nguyen, MD) QD301: CAR-T Cell Therapy for Lupus (featuring Philip Mease, MD and Cayla Alexander, DNP) QD302: Unweanable PMR (featuring Jack Cush, MD, and Leilani Law, APN) QD303: Weakness with Fibromyalgia (featuring Jack Cush, MD, and Leilani Law, APN)

Dr. Jack Cush reviews the news and journal reports from RheumNow.com, including info on scleroderma, dermatomyositis and malignancy, rheumatologist and APP salaries concerns.

Watch our kickoff webinar for this month's Mission: APP — Partners in Care campaign. Our panel of rheumatologists and experienced advanced practice providers share insights into hiring, onboarding, training, compensation, and more. Panelists: Philip Mease, MD Cayla Alexander, DNP, ARNP Kori Dewing, DNP, ANP-BC, ARNP Jack Cush, MD, Moderator

Dr. Jack Cush reviews the news and reports from this past week on RheumNow.com, including reports on FDA resurrections, FM seasonal worsening, and do you fight switch or swap biologics in PsA TNFi nonresponders?

The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects. Features Dr. Jack Cush, Editor at RheumNow.com. SHOW NOTES 1. Retrospective study of 39 pts w/ MDA5 + DM-ILD Rx w baricitinib. 31 (79.5%) had improvement in Gottron’s, heliotrope, dyspnea, HRCT score, ferritin, LDH, steroid dose & 6 mo survival (87% vs. 70%, p = 0.047). https://t.co/RCTbBsCkeV 2. Pulse Steroids and Mycophenolate in Juvenile Dermatomyositis JAMA Dermatology has published a pilot study demonstrating the safety and efficacy of intermittent intravenous methylprednisolone pulse (IVMP) therapy plus mycophenolate in 28 patients with JDM. https://t.co/i2HBycbWY9 3. Myelodysplastic & chr myelomonocytic leukemia pts rarely get lupus. Review of 19 w/ SLE & 5 w/ CLE; these were older (65 yrs), more male (15M/9F), w/ less renal [10%] & articular [36%] Dz w/ less dsDNA [32%]. Thought to be clonal inflammatory, & not autoinflammatory, process. https://t.co/EAvkJm6GQs 4. Serious infections w/ adalimumab. Marketscan MarketScan claims study (1/17-12/20) of ADA Rx in Hidradenitis Supprativa (n 1650) or psoriasis(8699). Risk of SIE & hospitalization greater w/ HS (HR 1.53); esp for sepsis & GU infxnhttps://t.co/2qa7O2v6fm 5. No risk of MACE seen w/ initiation of IL-17(R)A inhib. French study of 34 241 ipts Rx IL-17(R)Ai and 381 MACEs. MACE risk was not elevated (OR, 1.25 [95% CI, 0.75-2.08] vs TNF-α inhibitors. https://t.co/WcjgRhr8mj 6. Genetic Risks and Severe Cutaneous Reactions to Allopurinol A matched cohort study shows that HLA-B*58:01 and HLA-A*34:02 are strongly associated with allopurinol-induced severe cutaneous adverse reactions (SCARs), these alleles were absent in more than one-third of those https://t.co/NLpHVhr9Ww 7. Western Australia study of 1854 SLE pts (median 40 yrs old). Interstitial lung disease was seen in in 3.8% of SLE, 26 fold more than controls. Risk factors for ILD included older age, smoking and serositis. SLE-ILD pts had higher mortality rates (MR 52.0, CI 37.0–71.1). 8. 25-Hydroxyvitamin D levels and Lupus Outcomes Lupus patients entering a prospective cohort study with low vitamin D levels faced doubled all-cause mortality risk and tripled risk for major cardiovascular events during follow-up averaging 6 years, researchers said. https://t.co/CYwVy7ls7y 9. ACR2025 Non-Renal Lupus Guidelines – from ACR Convergence 2025 10. 900,000 vs 9 It takes about 900,000 minutes to become a board-certified dermatologist. At that point, you might be very skilled and well-informed. It takes less than nine minutes to make your patient feel seen, understood and reassured. If you skip the 9 minutes, you wasted the 900,000 https://t.co/o7BaWjS4HB

Replay of RheumNow Live 2025 - Vasculitis Featuring: - Dr. Michael Wechsler: Management of EGPA in 2025 - Dr. Rennie Rhee: Imaging in Vasculitis - Dr. Richard Conway: Modern Treatment of PMR

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. Check out: RNL 2026 – Feb 7 8 2026 DFW RheumNow.live

Replay of RheumNow Live 2025 - Spondyloarthritis Sponsored by AbbVie Featuring: Dr. Desiree van der Heidje - Advances in Treatment of Spondyloarthritis Dr. Jennifer Cather - Progress in Hidradenitis Supprativa Dr. Catherine Bakewell - Imaging Evaluation of Spondyloarthritis

Replay of RheumNow Live 2025 - Psoriatic Arthritis Sponsored by AbbVie Featuring: Dr. Alexis Ogdie - Can Aggressive Treatment of Psoriasis Prevent PsA? Dr. Artie Kavanaugh - Combination Biologic Therapies in PsA Dr. Kenneth Gordon - Head-to-head Studies in Psoriatic Disease – What have we learned?

Featuring: Dr. Jeffrey Curtis: AI applied to Rheumatoid Arthritis Care: Practically (Not) Perfect Dr. Una Makris: Key Considerations When Managing Older Adults with RA Dr. Bryant England: Who will manage multimorbidity in RA

A JAKi in GCA- Phase 3 Results Through 2 Years Sponsored by AbbVie Medical Affairs + Health Impact

A focused discussion on updates in spondyloarthritis, including emerging data, treatment strategies, and real-world care considerations. Hear expert perspectives and practical takeaways shaping SpA management today.

A focused conversation on the latest in CAR-T from emerging data and treatment strategies to real-world challenges in diagnosis and management. Hear expert perspectives, clinical pearls, and what’s shaping CAR-T practice right now.

A focused conversation on the latest in psoriatic arthritis care — from emerging data and treatment strategies to real-world challenges in diagnosis and management. Hear expert perspectives, clinical pearls, and what’s shaping PsA practice right now.

A focused conversation on the latest in psoriatic arthritis care - from emerging data and treatment strategies to real-world challenges in diagnosis and management. Hear expert perspectives, clinical pearls, and what's shaping PsA practice right now.

Stay plugged into the conversations, discoveries, and breakthroughs moving rheumatology forward. Real updates. Real context. For clinicians who never stop learning.

Dr. Jack Cush recaps ACR2025 with suggestions on how to best learn ACR25 content from RheumNow.com and our Videos and podcasts.

NEPTUNUS: Ianalumab in Sjogren's Pulmonary hypertension in Sarcoidosis

Restoring B Cell Compartments with CAR T: Molecular Data is Here CAR-T: The Future

Revised Classification Criteria in axSpA https://www.youtube.com/watch?v=voFJrQo1ANU NSAID Addition Helps the Spine but not the Hips https://www.youtube.com/watch?v=wTKMC1MTwpE Biomarker Discovery in axSpA https://www.youtube.com/watch?v=X8Sc_3oBSVA Sexual Function in axSpA https://www.youtube.com/watch?v=r4_Nsh7e_oo Coping Strategies in axSpA https://www.youtube.com/watch?v=z9KdNuOu4nI "ROC-SpA Study" https://www.youtube.com/watch?v=kIEN39XRsSM Why do patients stay in clinical trials? https://www.youtube.com/watch?v=pVIBoN0jO2o What to do after first TNR failure in axSpA? https://www.youtube.com/watch?v=PVSyq_Y5-PE

ILD in Patients with Connective Tissue Disease Fiber and Methotrexate RA ILD Prediction: simple as a dipstick? "Leftover Pain in Inflammatory Arthritis"

From Pain to Wellness in PsA Secukinumab vs Ustekinumab in PsA Izokibep: still enthused about enthesitis? Using Digital Apps to Modify Pain in axSpA

"ROC-SpA Study" Secukinumab vs Ustekinumab in PsA RA ILD Prediction: simple as a dipstick? Sjogren's Disease: PROs as a Filter for Precision Medicine Why do patients stay in clinical trials? Using Digital Apps to Modify Pain in axSpA IgG4: Rare but Treatable!

From Pain to Wellness in PsA IL-2 Therapy in SLE? Maybe Sexual Function in axSpA "Fact or Fiction: Trinetics Research at ACR" CD1/BCMA Dual Targeting: One too many targets in SLE Hydroxychloroquine Blood Levels The Great Debate: AI in Rheumatology Coping Strategies in axSpA "What to do After First TNR Failure in axSpA"

Join panelists Drs. Brian Jaros, Akhil Sood and Michael Putman as they recap highlights from Day 4, the final day of the 2025 ACR Convergence meeting in Chicago.

Join RheumNow Faculty Drs. Shelia Reyes, Mike Putman, Bella Mehta, and Jack Cush as they discuss highlights and key takeaways from the Day 3 Recap, at the 2025 ACR Convergence meeting in Chicago.

Screen RA ILD Properly Rheumatoid Arthritis Highlights Predicting Rheumatoid Arthritis GDF-15: How Depression is Related to Lung Disease in RA

"Leftover Pain in Inflammatory Arthritis" Another Specialized Biomarker in PsA Secrets and Pearls in Rheumatology What's the latest in PsA?

GDF-15: How Depression is Related to Lung Disease in RA What Can we do About Chronic Pain? What's the latest in PsA? What to do after first TNR failure in axSpA?

Secrets and Pearls in Rheumatology Addressing Lupus Nephritis Timely Fake Rheum Diagnostic Dilemmas Rheumatoid Arthritis Highlights Restoring B Cell Compartments with CAR T: Molecular Data is Here Predicting Rheumatoid Arthritis h What Causes Infection in Vasculitis? Is it All About the Weight Loss? Izokibep: still enthused about enthesitis? T Cell Engagers: Are we engaged? Fiber and Methotrexate

Spondyloarthritis: The CLASSIC Study "Leftover Pain in Inflammatory Arthritis" NeuroImmune Modulation in RA: Results of the RESET RA Trial Change it or Keep it? TNF in Axial SpA Perspectives on CAR T Therapy Addressing Lupus Nephritis Early Addressing Lupus Nephritis Aggressively CAR-T: The Future Biomarker Discovery in axSpA Another Specialized Biomarker in PsA Revised Classification Criteria in axSpA

Catching AxSpA Early: Closing the Diagnostic Gap Early Peripheral SpA: Is it okay to stop treatment sometimes? Difficult to Manage axSpA Tofacitinib in AxSpA in Developing Countries Late-Breaking Trials in axSpA and PsA Durability and Safety of Bimekizumab Biologics Improve Sexual Function in axSpA Multidimensional Pain inventory in Axial SpA Spondyloarthritis: The CLASSIC Study Change it or Keep it? TNF in Axial SpA "Leftover Pain in Inflammatory Arthritis"

B Cell Depletion: Check the Lymph Node "Next Generation T-Cell Engager: The Future" Off the Shelf: CAR-T Combining CAR-T with CAR-Treg All in One CAR-T Therapy: Where is it Heading? Safety of CAR-T New Paradigms in RA Treatment Perspectives on CAR T Therapy

Wired for Success: Vagal Nerve Therapy in RA RA: Does upfront TNFi save heartache? New Paradigms in RA Treatment